EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children’s Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small molecule, RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central…
eTurboNews raksti ir paredzēti tikai abonentiem. Abonements ir BEZMAKSAS.
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
KAS IZŅEMT NO ŠĪ RAKSTA:
- , a clinical stage drug and device company, in collaboration with the Texas Children’s Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small molecule, RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central….
- eTurboNews raksti ir paredzēti tikai abonentiem.
- Abonements ir BEZMAKSAS.
